Advertisement

Antimykotika

  • Uwe Fricke

Zusammenfassung

Antimykotika werden entsprechend der Bedeutung von Pilzinfektionen der Haut und Schleimhäute zu etwa 90% als Lokaltherapeutika eingesetzt. Insge-samt nimmt die Verordnung seit 1996 kontinuierlich ab. Lediglich die topischen Antimykotikakombinationen haben 2003 erstmals wieder deutlich zugenom-men.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abeck D, Gruseck E, Korting HC, Ring J (1996): Onychomykose: Epidemiologic, Pathogenese, Klinik, Mikrobiologie und Therapie. Dtsch Ärztebl 93: A-2027–2032.Google Scholar
  2. Akpan A, Morgan R (2002): Oral candidiasis. Postgrad Med J 78:455–459.PubMedCrossRefGoogle Scholar
  3. Albougy HA, Naidoo S (2002): A systematic review of the management of oral candidiasis associated with HIV/AIDS. J South African Dent Ass 57: 457–466.Google Scholar
  4. Alston SJ, Cohen BA, Braun M (2003): Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. Pediatrics 111:201–203.PubMedCrossRefGoogle Scholar
  5. Amichai B, Grunwald MH (1998): Adverse drug reactions of the new oral antifungal agents — terbinafine, fluconazole, and itraconazole. Int J Dermatol 37:410–415.PubMedCrossRefGoogle Scholar
  6. Area E, Tastan HB, Akar A, Kurumlu Z, Gur AR (2002): An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J Dermatol Treat 13: 3–9.CrossRefGoogle Scholar
  7. Bell-Syer SEM, Hart R, Crawford F, Torgerson DJ, Tyrell W, Russell I (2003): Oral treatments for fungal infections of the skin of the foot (Cochrane Review). In: The Cochrane Library, Issue 2 2003. Oxford: Update Software.Google Scholar
  8. Bennett ML, Fleischer AB, Loveless JW, Feldman SR (2000): Oral griseofulvin remains the treatment of choice for tinea capitis in children. Ped Dermatol 17: 304–309.CrossRefGoogle Scholar
  9. Blaschke-Hellmessen R, Buchmann H, Schwarze R (1996): Einfluß oral verabreich-ter Polyenantibiotika auf die Hefepilzbesiedlung des Darmtraktes: Möglich-keiten und Grenzen. Mycoses 39(Suppl 1): 33–39.PubMedCrossRefGoogle Scholar
  10. Bodman MA, Feder L, Nace AM (2003): Topical treatments for onychomycosis. A historical perspective. J Am Podiatr Med Ass 93:136–141.Google Scholar
  11. Casciano J, Amaya K, Doyle J, Arikian S, Shear N, Haspel M, Kahler K (2003): Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag Care 12: 47–54.PubMedGoogle Scholar
  12. Chan YC, Friedlander SF (2004): New treatments for tinea capitis. Curr Opin Infect Dis 17: 97–103.PubMedCrossRefGoogle Scholar
  13. Crawford F, Young P, Godfrey C, Bell-Syer SEM, Hart R, Brunt E, Russel I (2002): Oral treatments for toenail onychomycosis. Arch Dermatol 138:811–816.PubMedCrossRefGoogle Scholar
  14. Crawford F, Hart R, Bell-Syer S, Torgerson D, Young P, Russell I (2003): Topical treatments for fungal infections of the skin and nails of the foot (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.Google Scholar
  15. Darkes MJM, Scott LJ, Goa KL (2003): Terbinafine. A review of its use in onychomycosis in adults. Am J Clin Dermatol 4:39–65.PubMedCrossRefGoogle Scholar
  16. Deutsche Dermatologische Gesellschaft und Deutschsprachige Mykologische Gesell-schaft (2000): LeitlinieTinea der freien Haut. http://www.uni-duesseldorf.de/WWW/AWMF/ll/derm-m01.htm.Google Scholar
  17. Deutsche Dermatologische Gesellschaft und Deutschsprachige Mykologische Gesellschaft (2002): Leitlinie Onychomykose. http://www.uni-duesseldorf.de/WWW/AWMF/ll/derm-m02. htm.Google Scholar
  18. Devaraj A, O’Beirne JP, Veasey R, Dunk A (2002): Interaction between warfarin and topical miconazole cream. Br Med J 325: 77.CrossRefGoogle Scholar
  19. Dinnendahl V, Fricke U (Hrsg) (2004): Arzneistoff-Profile. Basisinformation über arzneiliche Wirkstoffe. Stammlieferung 1982 mit 1. bis 19. Ergänzungslieferung 2004, Govi-Verlag, Eschborn.Google Scholar
  20. Ellis D (2002): Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49(Suppl S1):7–10.PubMedCrossRefGoogle Scholar
  21. Evans EGV, Sigurgeirsson B for the LION study group (1999): Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Brit Med J 318:1031–1035.PubMedCrossRefGoogle Scholar
  22. Goa KL, Barradell LB (1995): Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50: 658–690.PubMedCrossRefGoogle Scholar
  23. Grant SM, Clissold SP (1989): Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310–344.PubMedCrossRefGoogle Scholar
  24. Grant SM, Clissold SP (1990): Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39: 877–916.PubMedCrossRefGoogle Scholar
  25. Grotzsche PC, Johansen HK (2003): Nystatin prophylaxis and treatment in severely immunodepresses patients (Cochrane Review): In: The Cochrane Library, Issue 2 2003. Oxford: Update Software.Google Scholar
  26. Gupta AK (2002): Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J Am Pediatr Med Assoc 92: 272–286.Google Scholar
  27. Gupta AK, Einarson TR, Summerbell RC, Shear NH (1998): An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 55: 645–674.PubMedCrossRefGoogle Scholar
  28. Gupta AK, Shear NH (1999): The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Dermatol Venereol 13:1–13.PubMedCrossRefGoogle Scholar
  29. Gupta AK, Lynde CW, Konnikov N (2001): Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 44: 485–491.PubMedCrossRefGoogle Scholar
  30. Haria M, Bryson HM (1995): Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 49:103–120.PubMedCrossRefGoogle Scholar
  31. Haria M, Bryson HM, Goa KL (1996): Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51:585–620.PubMedCrossRefGoogle Scholar
  32. Haugh M, Helou S, Boissel JP, Cribier BJ (2002): Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol 147: 118–121.PubMedCrossRefGoogle Scholar
  33. Higgins EM, Fuller LC, Smith CH (2000): Guidelines for the management of tinea capitis. Br J Dermatol 143: 53–58.PubMedCrossRefGoogle Scholar
  34. Hornstein OP, Nürnberg E (Hrsg) (1985): Externe Therapie von Hautkrankheiten: Pharmazeutische und medizinische Praxis. Georg Thieme Verlag, Stuttgart, New York, pp. 304–315.Google Scholar
  35. Lacour M, Zunder T, Huber R, Sander A, Daschner F, Frank U (2002): The pathogenic significance of intestinal Candida colonization — A systematic review from an interdisciplinary and environmental medical point of view. Int J Hyg Environ Health 205: 257–268.PubMedCrossRefGoogle Scholar
  36. Male O (1981): Medizinische Mykologie fur die Praxis. Georg Thieme Verlag, Stuttgart, New York.Google Scholar
  37. McClellan KJ, Wiseman LR, Markham A (1999): Terbinafine. An update of its use in superficial mycoses. Drugs 58:179–202.PubMedCrossRefGoogle Scholar
  38. Merk HF (1993): Antimykotika. Teil I und II. Hautarzt 44: 191–199 und 257–267.PubMedGoogle Scholar
  39. Niewerth M, Korting HC (1999): Management of onychomycoses. Drugs 58:283–296.PubMedCrossRefGoogle Scholar
  40. Niewerth M, Korting HC (2000): The use of systemic antimycotics in dermato-therapy. Eur J Dermatol 10:155–160.PubMedGoogle Scholar
  41. Patton LL, Bonito AJ, Shugars DA (2001): A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Pathol Oral Radiol Endod 92: 170–179.CrossRefGoogle Scholar
  42. Pierard GE, Arrese JE, Pierard-Franchimont C (1996): Treatment and prophylaxis of tinea infections. Drugs 52: 209–224.PubMedCrossRefGoogle Scholar
  43. Powderly WG, Mayer KH, Perfect JR (1999): Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses 15:1405–1412.PubMedCrossRefGoogle Scholar
  44. Quintanar-Guerrero D, Ganem-Quintanar A, Tapia-Olguin P, Kaliar YN, Buri P (1998): The effect of keratolytic agents on the permeability of three imidazole antimycotic drugs through the human nail. Drug Dev Ind Pharm 24: 685–690.PubMedCrossRefGoogle Scholar
  45. Rigopoulos D, Katoulis AC, Ioannides D, Georgala S, Kalogeromitros D, Bolbasis I et al (2003): A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol 149:151–156.PubMedCrossRefGoogle Scholar
  46. Ring J, Fröhlich HH (1985): Wirkstoffe in der dermatologischen Therapie, 2. Aufl Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, pp 133–136 und 211–213.CrossRefGoogle Scholar
  47. Roberts DT, Taylor WD, Boyle J (2003): Guidelines for treatment of onychomycosis. Br J Dermatol 148:402–410.PubMedCrossRefGoogle Scholar
  48. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EGV (2002): Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis. Arch Dermatol 138:353–357.PubMedCrossRefGoogle Scholar
  49. Silingardi M, Ghirarduzzi A, Tincani E, Iorio A, Iori I (2000): Miconazole oral gel potentiates warfarin anticoagulant activity. Thromb Haemost 83: 794–795.PubMedGoogle Scholar
  50. Simon C, Stille W (2000): Antibiotika-Therapie in Klinik und Praxis, 10. Auflage. Schattauer, Stuttgart-New York, S. 330–336.Google Scholar
  51. Steigleder GK (1993): Therapie der Hautkrankheiten, 4. Aufl. Georg Thieme Verlag, Stuttgart, New York.Google Scholar
  52. Thirion DJ, Zanetti LA (2000): Potentiation of warfarin’s hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy 20:98–99.PubMedCrossRefGoogle Scholar
  53. Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000): Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 38:111–180.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Uwe Fricke
    • 1
  1. 1.Institut für Pharmakologie der Universität zu KölnKöln

Personalised recommendations